Charles River Laboratories, Inc.'s CDMO and Cell Solutions Business

Charles River Laboratories, Inc. is a US-based provider of essential drug development services, including biologics testing and manufacturing, to support the pharmaceutical industry effectively. Charles River Laboratories operates as a prominent player in the life sciences sector, offering extensive services that assist in drug discovery and development. The company has undergone strategic enhancements to strengthen its operational capabilities.

Its headquarters are located in Wilmington, Massachusetts, USA. In February 2026, GI Partners agreed to acquire Charles River Laboratories, Inc. 's CDMO and Cell Solutions Business, with financial terms undisclosed. The acquisition is expected to bolster the company's services and expand its global presence.

Charles River Laboratories specializes in providing comprehensive solutions that support drug discovery and development across various stages of the pharmaceutical lifecycle. Their core offerings include integrated drug discovery services, preclinical testing, clinical development support, and biologics testing and manufacturing solutions. These services cater to a diverse client base, including biotechnology firms, pharmaceutical companies, and academic institutions engaged in life sciences research. Charles River's innovations are designed to enhance the efficiency and effectiveness of drug development processes, aiming to reduce the time and costs associated with bringing new therapeutics to market.

Geographically, their products and services are utilized by clients in North America, Europe, and Asia-Pacific regions, reflecting their global footprint in the life sciences sector. Charles River Laboratories generates revenue through its broad portfolio of scientific and regulatory services, which are structured primarily through business-to-business (B2B) transactions. Clients engage in contracts for services such as genetically engineered animal models, preclinical testing, and clinical trial management, often through custom agreements that align with specific project needs. This may involve fixed fees for particular studies or ongoing partnerships that adapt to evolving client requirements in drug development.

The company’s flagship services, such as their IND-enabling studies and biologics contract manufacturing, emphasize their commitment to delivering tailored solutions that meet regulatory standards while supporting the development of safe and effective therapeutic products. The acquisition by GI Partners in February 2026 is anticipated to enhance Charles River Laboratories, Inc. 's CDMO and Cell Solutions Business' service offerings and foster expansion in global markets. This strategic move is designed to support the development of new products and enhance operational capabilities, allowing the company to better serve its clients in the evolving life sciences landscape.